Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 16/20 | 0.52 |
| ▸ | PPARA | Q07869 | 16/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747418 | 0.94 | PPARG (0.56) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4747030 | 0.93 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL4748435 | 0.93 | KDR (0.59) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4747572 | 0.93 | KDR (0.59) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4746249 | 0.91 | FFAR1 (0.55) | KDRPPARGPPARAMAPTFFAR1 | |
| SCHEMBL4747967 | 0.91 | PPARG (0.53) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4747378 | 0.89 | KDR (0.58) | KDRPPARGPPARAMAPTFFAR1 | |
| SCHEMBL4748578 | 0.89 | KDR (0.58) | KDRPPARGPPARAMAPTFFAR1 | |
| SCHEMBL4747374 | 0.89 | KDR (0.58) | KDRPPARGPPARAMAPTFFAR1 | |
| SCHEMBL4747301 | 0.88 | POLB (0.59) | KDRPPARGPPARAMAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008117982-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING LIPID ACCUMULATION CONTAINING SAME | CRYSTAL GENOMICS, INC. (KR) | 2008-10-02 | — | — | WO | disclosed |